Nov 4, 4:40 PM ET
LeMaitre reported preliminary third-quarter 2026 sales of $68.0 million, up 11% from a year earlier, while diluted EPS fell 14% to $0.65 and operating income fell 13% to $17.7 million. The company kept its full-year 2026 outlook, guiding to sales of $274.8 million to $276.8 million and EPS of $2.77 to $2.82, and declared a $0.25 quarterly dividend. The company also bought certain vascular assets from B. Braun for $19.2 million in October.
- Q3 2026 net sales $68.0 million, up 11% (12% organic) from Q3 2025; diluted EPS $0.65 versus $0.75
- Q3 operating income $17.7 million versus $20.3 million a year earlier; the prior-year period included a $3.4 million employee retention tax credit benefit
- FY 2026 guidance: sales $274.8 million to $276.8 million and EPS $2.77 to $2.82; Q4 EPS guidance $0.70 to $0.75
- Quarterly dividend of $0.25 per share payable December 3, 2026, to holders of record on November 19, 2026
Read the filing on SEC.gov ↗
Aug 4, 4:39 PM ET
LeMaitre Vascular reported preliminary Q2 2026 results with net sales of $70.4 million, up 10% from a year earlier, and operating income of $20.4 million, up 26%. The company also gave guidance: full-year 2026 sales of $274.3 million to $278.3 million and diluted EPS of $2.84 to $2.94, while third-quarter operating income and EPS are guided below last year's levels, which included a one-time employee retention tax credit benefit.
- Q2 2026 net sales $70.4 million, up 10%; gross margin 72.1%, up 210 basis points; diluted EPS $0.74, up 23% from $0.60.
- Full-year 2026 guidance: sales $274.3 million to $278.3 million; EPS $2.84 to $2.94, midpoint up 15% from 2025 as reported.
- Q3 2026 guidance: EPS $0.66 to $0.71 and operating income $17.3 million to $18.8 million, both below Q3 2025 as reported, which included an employee retention tax credit benefit.
- Board approved a quarterly dividend of $0.25 per share, payable September 3, 2026, to holders of record on August 20, 2026.
Read the filing on SEC.gov ↗
May 5, 4:34 PM ET
LeMaitre Vascular reported preliminary first-quarter 2026 results, with net sales up 11% to $66.6 million and diluted EPS up 42% to $0.68 from a year earlier. Management said full-year 2026 guidance was increased, now projecting sales of $277 million to $283 million and EPS of $2.93 to $3.08.
- Q1 2026 net sales of $66.6 million, up 11% (10% organic) versus Q1 2025; gross margin 72.7%, up 350 basis points
- Q1 2026 diluted EPS of $0.68 versus $0.48 in Q1 2025; income from operations of $17.8 million, up 41%
- Full-year 2026 guidance: sales of $277 million to $283 million and EPS of $2.93 to $3.08; Q2 2026 sales guidance of $70.5 million to $72.5 million
- Quarterly dividend of $0.25 per share, payable June 4, 2026 to holders of record on May 21, 2026
Read the filing on SEC.gov ↗
Apr 14, 6:45 AM ET
LeMaitre Vascular director Bridget Ross notified the board on April 8, 2026 that she will not stand for re-election at the June 2, 2026 annual meeting, and she will serve until then. The board nominated David B. Roberts for a Class II seat to rebalance board classes; he conditionally resigned his Class I seat, and the board will shrink from eight to seven members. The filing describes these changes as administrative and states no disagreements with the company.
- Bridget Ross, Class II director, notified the board on April 8, 2026 of her intent not to stand for re-election
- David B. Roberts nominated as Class II director; he notified the board on April 9, 2026 of his conditional resignation as a Class I director
- Board size reduced from eight to seven members, effective upon Ross's departure; board to have two Class I, two Class II and three Class III directors
- Annual meeting to be held June 2, 2026
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.